Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pricing Strategies

Set Alert for Pricing Strategies

Generics Savings Once Again Could Help A Major US Health Care Reform Bill

A provision in the pending legislation on PBMs that would allow the US FDA to provide qualitative and quantitative information to ANDA sponsors about reference product's inactive ingredients could save hundreds of millions in spending.

Legislation Reimbursement

Betahistine Leads A Raft Of UK Rises In August

With multiple generic molecules experiencing treble-digit-percentage price increases in the UK in August, betahistine tablets led the month’s biggest risers, according to WaveData.

Market Intelligence Pricing Strategies

Beyond Viatris: Kiran Mazumdar-Shaw Talks Next Steps For Biocon Biologics

As Biocon Biologics completes its integration of the biosimilars front-end business that it acquired from former partner Viatris, Biocon founder and chairperson Kiran Mazumdar-Shaw talks to Generics Bulletin about how the firm is now capturing the full value of its biosimilars, while also looking at expanding into new markets previously unserved by Viatris.

Biosimilars M & A

Generics Bulletin Explains: The Changing US Generics Market

After a couple of years of heavy downwards pressure on US generics prices, prominent off-patent companies have pointed to a change in the pricing environment as several factors combine to reduce price erosion. Meanwhile, some firms are benefiting from first generic launches as others exit the market altogether, while injectables shortages continue to loom large.

Generic Drugs United States

Biocon: Slow Humira Biosimilar Uptake But Payer Landscape Evolving

Biocon bets on dual pricing strategy in the US amid a “more gradual” than expected uptake of biosimilar adalimumab but emphasizes that payer positions aren’t “definitive” yet.

Biosimilars Strategy

Three Remain Liable On UK Liothyronine Price Abuse – But Fines Slimmed On Appeal

Advanz Pharma has failed in its appeal against a £40.9m fine imposed by the UK’s Competition and Markets Authority for its historical pricing practices for liothyronine tablets.

Legal Issues Enforcement

Canadian Industry Reaches Fresh Pricing Agreement

The Canadian Generic Pharmaceutical Association and the pan-Canadian Pharmaceutical Alliance have agreed a new three-year national pricing initiative for generic medicines.

Deals Regulation

Teva Pays Out $225m To Settle Criminal Price-Fixing Charges In US

Teva has agreed to pay a $225m fine, as well as donating $50m worth of medicines and divesting a product from its portfolio, as part of a settlement with the US Department of Justice over criminal price-fixing charges. Meanwhile, Glenmark has also struck a $30m settlement with the DoJ.

Legal Issues Deals

UK Risks Becoming ‘Economically Unviable’ For Biosimilars

Amid increasing financial pressure from the VPAS rebate scheme and a lack of a national uptake strategy, the BGMA has warned that the UK risks losing its leading position in European biosimilars and could become altogether “economically unviable” for biosimilars suppliers.

Market Intelligence Biosimilars

Organon Welcomes Prospect Of Interchangeability ‘Boost’ – But Pricing Still Key

Organon’s CEO Kevin Ali talked at length about the company’s launch of its Hadlima biosimilar version of Humira in the US during the company’s Q2 earnings call, following recent news it was looking to file for an interchangeability designation.

Biosimilars Strategy

Medicare Price Negotiation List Remains A Puzzle, Even For Those That Are (Probably) On It

Highly anticipated list will determine the Medicare Part D drugs subject to negotiated prices in 2026. Under the law, the list cannot be subject to administrative or judicial review, so the stakes are high. As patent and sales statuses shift, the Pink Sheet offers a baker's dozen of possible drugs.

Medicare Reimbursement

July Wholesaler Hike Sees UK Olanzapine Prices Spike

July brought UK price spikes for multiple presentations of generic olanzapine orodispersible tablets. Market researcher WaveData reveals the reason behind the increases.

Market Intelligence Pricing Strategies

Biosimilars Could Give Brands the Boot Mid-Year Under Amendment Added to Senate PBM Reform Bill

However, the low CBO score attached to the measure may suggest PBMs might not be incentivized to follow through on the congressional permission.

Legislation Biosimilars

Coherus’s Low List Price Adalimumab Stacking Up PBM And Pharmacy Partnerships

Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader. 

Biosimilars Reimbursement

‘We Are Well Positioned To Succeed’: Organon On US Adalimumab Entry

With Organon’s Humira biosimilar Hadlima reaching the US market earlier this month, the company’s biosimilars commercial lead in the market, Jon Martin, spoke to Generics Bulletin about the seminal event, as well as the company’s commercialization-only business model.

Biosimilars Commercial

‘You Have To Play On A Pretty Broad Part Of The Piano’: Fresenius Kabi On Biosimilar Commitment

During a broad and wide-ranging interview, taking place in the aftermath of Fresenius Kabi’s entry into the US adalimumab biosimilar market, president of the firm’s Biopharma business, Michael Schönhofen, talks about Kabi’s ambitions in the space, and how it is positioned to be a long-term player.

Biosimilars Commercial
See All